(Q38313704)

2 September 2017

title

Chemerin is highly expressed in hepatocytes and is induced in non-alcoholic steatohepatitis liver (English)

1 reference

non-alcoholic steatohepatitis

2 September 2017

0 references

1 reference

Sabrina Krautbauer

1

1 reference

2 September 2017

Josef Wanninger

2

1 reference

2 September 2017

Kristina Eisinger

3

1 reference

2 September 2017

Yvonne Hader

4

1 reference

2 September 2017

Michael Beck

5

1 reference

2 September 2017

Andrea Kopp

6

1 reference

2 September 2017

Andreas Schmid

7

1 reference

2 September 2017

Thomas S Weiss

8

1 reference

2 September 2017

Christoph Dorn

9

1 reference

2 September 2017

Christa Buechler

10

1 reference

2 September 2017

publication date

29 July 2013

1 reference

Experimental and Molecular Pathology

2 September 2017

published in

1 reference

2 September 2017

volume

95

1 reference

2 September 2017

issue

2

1 reference

2 September 2017

page(s)

199-205

1 reference

Sterol regulatory element-binding protein 2 (SREBP2) activation after excess triglyceride storage induces chemerin in hypertrophic adipocytes

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.07.009

Soluble CD163 is not increased in visceral fat and steatotic liver and is even suppressed by free fatty acids in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.07.009

Expression of Human Chemerin Induces Insulin Resistance in the Skeletal Muscle but Does Not Affect Weight, Lipid Levels, and Atherosclerosis in LDL Receptor Knockout Mice on High-Fat Diet

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.07.009

Adipose tissue, inflammation, and cardiovascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.07.009

Human articular chondrocytes express ChemR23 and chemerin; ChemR23 promotes inflammatory signalling upon binding the ligand chemerin(21-157).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.07.009

Chemerin is a novel adipokine associated with obesity and metabolic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.07.009

Does hepatic steatosis affect drug metabolizing enzymes in the liver?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.07.009

Inflammation and insulin resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.07.009

Identification of chemerin as a novel FXR target gene down-regulated in the progression of nonalcoholic steatohepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.07.009

Chemerin induces CCL2 and TLR4 in synovial fibroblasts of patients with rheumatoid arthritis and osteoarthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.07.009

Chemerin: at the crossroads of inflammation and obesity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.07.009

Chemerin exacerbates glucose intolerance in mouse models of obesity and diabetes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.07.009

Disruption of the chemokine-like receptor-1 (CMKLR1) gene is associated with reduced adiposity and glucose intolerance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.07.009

The role of adipose tissue dysfunction in the pathogenesis of obesity-related insulin resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.07.009

Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.07.009

Insulin decreases inflammatory signal transcription factor expression in primary human liver cells after LPS challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.07.009

Adipocytokines and liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.07.009

Interleukin-1beta induces the novel adipokine chemerin in adipocytes in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.07.009

Serum chemerin and vaspin in non-alcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.07.009

Animal models of NASH: getting both pathology and metabolic context right

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.07.009

Epithelial cells in fetal intestine produce chemerin to recruit macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.07.009

Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.07.009

Serum chemerin levels vary with time of day and are modified by obesity and tumor necrosis factor-{alpha}.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.07.009

A stress signaling pathway in adipose tissue regulates hepatic insulin resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.07.009

Mechanisms of disease: adipocytokines and visceral adipose tissue--emerging role in nonalcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.07.009

NIH Image to ImageJ: 25 years of image analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.07.009

Chemerin is a novel adipocyte-derived factor inducing insulin resistance in primary human skeletal muscle cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.07.009

Chemerin correlates with markers for fatty liver in morbidly obese patients and strongly decreases after weight loss induced by bariatric surgery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.07.009

Activated hepatic stellate cells express keratinocyte growth factor in chronic liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.07.009

Peroxisome Proliferator-Activated Receptor α Protects against Obesity-Induced Hepatic Inflammation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.07.009

Highly efficient and low-cost method to isolate human blood monocytes with high purity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.07.009

Insulin and metformin regulate circulating and adipose tissue chemerin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.07.009

Charitable State-Controlled Foundation Human Tissue and Cell Research: Ethic and Legal Aspects in the Supply of Surgically Removed Human Tissue For Research in the Academic and Commercial Sector in Germany

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.07.009

The role of cytokines in non-alcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.07.009

Adiponectin reduces connective tissue growth factor in human hepatocytes which is already induced in non-fibrotic non-alcoholic steatohepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.07.009

Kupffer cells mediate leptin-induced liver fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.07.009

Adiponectin induces the transforming growth factor decoy receptor BAMBI in human hepatocytes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.07.009

Lipid accumulation impairs adiponectin-mediated induction of activin A by increasing TGFbeta in primary human hepatocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.07.009

Adiponectin upregulates hepatocyte CMKLR1 which is reduced in human fatty liver.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.07.009

Systemic chemerin is related to inflammation rather than obesity in type 2 diabetes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.07.009

Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.07.009

Serum levels of omentin, chemerin and adipsin in patients with biopsy-proven nonalcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.07.009

Chemerin reveals its chimeric nature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.07.009

Chemerin is an independent marker of the metabolic syndrome in a Caucasian population--a pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.07.009

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.YEXMP.2013.07.009

1 reference

2 September 2017

1 reference